Cyclophosphamide News and Research

RSS

Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.

Younger mismatched donors offer new hope for blood cancer patients

Blood cancer patients who cannot find a closely matched stem cell donor may have more transplant options than previously thought.

21 Aug 2026

Dual immunotherapy with neoadjuvant chemotherapy shows encouraging activity in ERBB2-negative breast cancer

A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given prior to surgery for patients with high-risk, early-stage HER2-negative breast cancer, according to phase 2 clinical trial results from the ongoing I-SPY2 clinical trial platform.

30 Jul 2026

Early glucocorticoid tapering reduces damage in vasculitis maintenance therapy

Glucocorticoids are the cornerstone of initial vasculitis treatment, used to rapidly control inflammation and protect vital organs.

4 Jun 2026

Targeted therapy treats mixed histiocytosis following multiple skull relapses

Mixed histiocytosis (Langerhans cell histiocytosis [LCH] / Erdheim-Chester disease [ECD]) developing after treatment for initial skull LCH is not well recognized.

13 Apr 2026

Nanomedicine offers targeted solutions for breast cancer treatment

Breast cancer (BCA) is one of the most common cancers worldwide, with high mortality and morbidity in women.

10 Apr 2026

Precision medicine tools offer hope for patients with rare blood cancers

Personalized approaches have dramatically improved outcomes for many patients with non-Hodgkin B-cell lymphomas—blood cancers that arise in immune cells called B cells—yet the same is not true for patients with more rare lymphoma types that originate in immune cells called T cells.

9 Apr 2026

Fifteen-year follow up reveals cure potential in follicular lymphoma

Unlike some other forms of lymphoma, advanced stage follicular lymphoma is considered incurable. But a new analysis of long-term data on patients treated for the disease years ago with standard regimens of immunotherapy and a chemotherapy combination known as CHOP suggests that many of those patients can now be considered cured.

26 Feb 2026

Preoperative radiation may enhance treatment response in patients with HR-positive, HER2-negative breast cancer

Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative breast cancer when administered in combination with pembrolizumab (Keytruda) and chemotherapy and led to improved treatment responses prior to surgery, according to the results of the phase II P-RAD clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

11 Dec 2025

Expanded donor matching makes stem cell transplants accessible

For years, the search for a stem cell donor has felt like a quest for a rare key-one that fits a lock with eight intricate tumblers, each representing a genetic marker.

10 Dec 2025

Most T-cell/histocyte-rich large B-cell lymphoma patients can safely receive a less toxic treatment

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

8 Dec 2025

Simple blood test may be a better guide treatment for ovarian cancer

More than 300,000 women are diagnosed with ovarian cancer globally each year.

12 Nov 2025

Advances in diagnosis and management of systemic light chain amyloidosis

Systemic light chain (AL) amyloidosis is a rare and life-threatening disorder characterized by the deposition of misfolded immunoglobulin light chains as insoluble amyloid fibrils in various tissues and organs, leading to progressive structural and functional impairment.

30 Oct 2025

Uterine corpus malignancies with pregnancy-like features lead to poor survival outcomes

A new review was published in Volume 12 of Oncoscience on September 4, 2025, titled "Prognostic significance of trophoblastic differentiation and β-hCG secretion in somatic malignancies of uterine corpus: A systematic review with survival analysis."

16 Sep 2025

Genetic mutation in some East Asians linked to aldehyde storm and increased liver disease risk

Researchers have identified the mechanism by which a common genetic mutation increases liver disease risk. Their findings suggest that healthy choices, such as increasing antioxidants and limiting exposure to smoke, may reduce the risk of this disease.

13 Sep 2025

Using machine learning framework to identify prognostic biomarkers in neuroblastoma

Neuroblastoma is the most common solid tumor in infants and accounts for nearly 15% of all pediatric cancer-related deaths.

11 Aug 2025

Lauric acid could be a key cancer-fighting compound in coconut oil

Virgin coconut oil and lauric acid show promise in inhibiting cancer cell growth and mitigating chemotherapy toxicity, paving the way for future therapies.

11 Aug 2025

Chemotherapy treatment linked to lasting cognitive changes in rats

Researchers at The City College of New York have linked chemotherapy treatment to lasting cognitive changes in rats – potentially shading light, for the first time, on cognitive problems some cancer survivors experience long after treatment ends.

31 Jul 2025

Low-dose olanzapine reduces chemo-induced nausea with fewer side effects

Chemotherapy-induced nausea and vomiting are among the most distressing side effects of anti-cancer treatment, particularly for those receiving highly emetogenic regimens such as anthracycline plus cyclophosphamide combinations.

24 Jul 2025

New approach makes mismatched stem cell transplants safer for blood cancer patients

Advances in blood stem cell transplants now make it possible for people with blood cancers to get safe and effective "mismatched" transplants that will potentially cure their disease, new UVA Cancer Center research reveals. The advances will allow far more people to receive the lifesaving treatment.

15 Jul 2025

NMDP and CIBMTR release updated guidelines to improve donor selection for transplants

NMDPSM, a global nonprofit leader in cell therapy, and its collaborative research program, CIBMTR (Center for International Blood and Marrow Transplant Research), have released revised donor and cord blood selection guidelines to enhance transplant outcomes for patients.

10 Jul 2025